Abstract
Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the BCR-ABL oncoprotein, presents its treatment based on tyrosine kinase inhibitors (TKIs), mainly imatinib. However, despite its clinical success, almost 30% of all CML patients demand alternative therapy. In this context, the development of drugs capable of overcoming TKIs resistance is imperative. The pterocarpanquinone-LQB-118 is a novel compound with anti-tumor effect in CML cells whose mechanism of action is being elucidated. Here, we demonstrate that in two CML cell lines exhibiting different biological characteristics, LQB-118 modulates NFκB subcellular localization, apparently independently of the AKT and MAPK pathways, partially inhibits proteasome activity, and alters the expression of microRNAs -9 and -21.
Keywords: Cancer, chronic myeloid leukemia, microRNA, multidrug resistance phenotype, NFκB, pterocarpanquinone-LQB-118.
Anti-Cancer Agents in Medicinal Chemistry
Title:NFκB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines
Volume: 15 Issue: 3
Author(s): Fernanda Costas C. de Faria, Maria Eduarda Bento Leal, Paula Sabbo Bernardo, Paulo R.R. Costa and Raquel C. Maia
Affiliation:
Keywords: Cancer, chronic myeloid leukemia, microRNA, multidrug resistance phenotype, NFκB, pterocarpanquinone-LQB-118.
Abstract: Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the BCR-ABL oncoprotein, presents its treatment based on tyrosine kinase inhibitors (TKIs), mainly imatinib. However, despite its clinical success, almost 30% of all CML patients demand alternative therapy. In this context, the development of drugs capable of overcoming TKIs resistance is imperative. The pterocarpanquinone-LQB-118 is a novel compound with anti-tumor effect in CML cells whose mechanism of action is being elucidated. Here, we demonstrate that in two CML cell lines exhibiting different biological characteristics, LQB-118 modulates NFκB subcellular localization, apparently independently of the AKT and MAPK pathways, partially inhibits proteasome activity, and alters the expression of microRNAs -9 and -21.
Export Options
About this article
Cite this article as:
de Faria Costas C. Fernanda, Bento Leal Eduarda Maria, Bernardo Sabbo Paula, Costa R.R. Paulo and Maia C. Raquel, NFκB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (3) . https://dx.doi.org/10.2174/18715206113139990108
DOI https://dx.doi.org/10.2174/18715206113139990108 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Marrow Reconstitution as a Relevant Model of Genetically Programmed Leukemia
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pleiotropic Effect of Mahanine and Girinimbine Analogs: Anticancer Mechanism and its Therapeutic Versatility
Anti-Cancer Agents in Medicinal Chemistry Cytomegalovirus Infection in Pediatric Immunocompromised Hosts
Infectious Disorders - Drug Targets Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Anti-Cancer Agents in Medicinal Chemistry How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets Secondary Neoplasms in Children Treated for Cancer
Current Pediatric Reviews Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Current Drug Discovery Technologies Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Discovery of BRM Targeted Therapies: Novel Reactivation of an Anticancer Gene
Letters in Drug Design & Discovery Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Cardiovascular & Hematological Agents in Medicinal Chemistry Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry An Overview of HDAC Inhibitors and their Synthetic Routes
Current Topics in Medicinal Chemistry New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry